Myotonic Dystrophy Market: Strong Pharma Growth Forecast Through 2034 - DelveInsight

DelveInsight's "Myotonic Dystrophy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myotonic Dystrophy, historical and forecasted epidemiology as well as the Myotonic Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get a Free sample for the Myotonic Dystrophy Market Report:
https://www.delveinsight.com/report-store/myotonic-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Myotonic Dystrophy Market Report:
* The Myotonic Dystrophy market size was valued approximately USD 89 million in 2023 and is anticipated to grow with a significant CAGR of 18.4% during the study period (2020-2034)
* In March 2026, The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 trial due to concerns related to certain preclinical pharmacology and toxicology studies. The Phase 2 trial is designed as a multiple ascending dose study evaluating PGN-EDODM1 in patients with Myotonic Dystrophy Type 1 (DM1). Importantly, the partial hold does not involve any issues with the blinded clinical data from the earlier Phase 1 FREEDOM study, which had previously been submitted to support the initiation of the FREEDOM2 trial in the United States. As part of ongoing discussions with the FDA, PepGen is providing additional analyses, including newly unblinded data from the FREEDOM study.
* In February 2026, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company focused on developing a novel class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCsTM), announced that the final findings from the completed Phase 1/2 MARINA® clinical trial evaluating delpacibart etedesiran (del-desiran) in patients with Myotonic Dystrophy Type 1 will be published in the February 19 edition of The New England Journal of Medicine. The research article is titled "An Antibody Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.
* In June 2025, Dyne Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to DYNE-101 for treating myotonic dystrophy type 1 (DM1). The company also shared an updated strategy for pursuing US Accelerated Approval for DYNE-101 in DM1, following a Type C meeting with the FDA and the review of new long-term functional data.
* In April 2025, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCsTM), announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to delpacibart etedesiran (del-desiran) for treating myotonic dystrophy type 1 (DM1). Del-desiran, an investigational therapy targeting the root cause of DM1-a progressive, often fatal neuromuscular disease with no approved treatments-is the first DM1 therapy to receive ODD in Japan. The drug has also received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the U.S. FDA, as well as Orphan designation from the European Medicines Agency (EMA).
* Within the 7MM, the EU4 and the UK accounted for approximately 353,191 diagnosed prevalent cases of Myotonic Dystrophy, with the number of cases projected to rise throughout the forecast period (2024-2034).
* Among the EU4 countries and the UK, Germany recorded the highest number of diagnosed prevalent Myotonic Dystrophy cases at 8,938 in 2023, followed by the UK and France. Conversely, Spain had the lowest diagnosed prevalent population within the EU4 and the UK that year.
* In 2023, Japan reported approximately 12,735 diagnosed prevalent cases of Myotonic Dystrophy, with these numbers projected to grow at a substantial CAGR.
* In 2023, Japan had roughly 1,834 myotonic dystrophy cases linked to gastrointestinal symptoms, 1,605 cases associated with cardiac dysrhythmias, 1,414 cases with sleep disorders, and 3,566 cases presenting other comorbidities.
* In 2023, adults accounted for the largest share of myotonic dystrophy cases in the 7MM, with an estimated 96,287 cases, compared to 9,075 cases among children.
* Key Myotonic Dystrophy Companies: EditForce, Inc., Arrowhead Pharmaceuticals, Inc., Vertex Pharmaceuticals, Pepgen Corporation, Avidity Biosciences, Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma, Dyne Therapeutics, Entrada Therapeutics, and others
* Key Myotonic Dystrophy Therapies: EF-210, ARO-DM1, VX-670, PGN-EDODM1, Delpacibart etedesiran, DM1 program, ENZ-001, JUV 161, DYNE-101, AOC 1001, Pitolisant, Tideglusib, Mexiletine, AMO-02, DYNE-101, ENTR-701, and others
* The Myotonic Dystrophy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myotonic Dystrophy pipeline products will significantly revolutionize the Myotonic Dystrophy market dynamics.

Myotonic Dystrophy Overview
Myotonic Dystrophy is a genetic disorder characterized by progressive muscle weakness and prolonged muscle contractions (myotonia). It affects multiple body systems, including the muscles, heart, eyes, and endocrine system. The condition is inherited and typically worsens over time, leading to difficulties with movement, coordination, and other complications such as cardiac issues and sleep disturbances. There are two main types-Type 1 (DM1) and Type 2 (DM2)-with DM1 being the more common and severe form.

To Know in detail about the Myotonic Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myotonic Dystrophy Market Forecast
https://www.delveinsight.com/sample-request/myotonic-dystrophy-market?utm_source=openp&utm_medium=pressrelease&utm_campaign=gpr

Myotonic Dystrophy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myotonic Dystrophy Epidemiology Segmentation:
The Myotonic Dystrophy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
* Total Prevalence of Myotonic Dystrophy
* Prevalent Cases of Myotonic Dystrophy by severity
* Gender-specific Prevalence of Myotonic Dystrophy
* Diagnosed Cases of Episodic and Chronic Myotonic Dystrophy

Download the report to understand which factors are driving Myotonic Dystrophy epidemiology trends @ Myotonic Dystrophy Epidemiology Forecast
https://www.delveinsight.com/sample-request/myotonic-dystrophy-market?utm_source=openp&utm_medium=pressrelease&utm_campaign=gpr

Myotonic Dystrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myotonic Dystrophy market or expected to get launched during the study period. The analysis covers Myotonic Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Myotonic Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myotonic Dystrophy Therapies and Key Companies
* EF-210: EditForce, Inc.
* ARO-DM1: Arrowhead Pharmaceuticals, Inc.
* VX-670: Vertex Pharmaceuticals
* PGN-EDODM1: Pepgen Corporation
* Delpacibart etedesiran: Avidity Biosciences
* DM1 program: Design Therapeutics
* ENZ-001: Enzerna
* JUV 161: Juvena Therapeutics
* DYNE-101: Dyne Therapeutics
* AOC 1001: Avidity Biosciences
* Pitolisant: Harmony Biosciences
* Tideglusib: AMO Pharma
* Mexiletine: Lupin
* AMO-02: AMO Pharma
* DYNE-101: Dyne Therapeutics
* ENTR-701: Entrada Therapeutics

Discover more about therapies set to grab major Myotonic Dystrophy market share @ Myotonic Dystrophy Treatment Market
https://www.delveinsight.com/sample-request/myotonic-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Myotonic Dystrophy Market Report
* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Myotonic Dystrophy Companies: EditForce, Inc., Arrowhead Pharmaceuticals, Inc., Vertex Pharmaceuticals, Pepgen Corporation, Avidity Biosciences, Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma, Dyne Therapeutics, Entrada Therapeutics, and others
* Key Myotonic Dystrophy Therapies: EF-210, ARO-DM1, VX-670, PGN-EDODM1, Delpacibart etedesiran, DM1 program, ENZ-001, JUV 161, DYNE-101, AOC 1001, Pitolisant, Tideglusib, Mexiletine, AMO-02, DYNE-101, ENTR-701, and others
* Myotonic Dystrophy Therapeutic Assessment: Myotonic Dystrophy current marketed and Myotonic Dystrophy emerging therapies
* Myotonic Dystrophy Market Dynamics: Myotonic Dystrophy market drivers and Myotonic Dystrophy market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Myotonic Dystrophy Unmet Needs, KOL's views, Analyst's views, Myotonic Dystrophy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.